209 related articles for article (PubMed ID: 15728888)
1. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.
Larsen RA; Pappas PG; Perfect J; Aberg JA; Casadevall A; Cloud GA; James R; Filler S; Dismukes WE
Antimicrob Agents Chemother; 2005 Mar; 49(3):952-8. PubMed ID: 15728888
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy.
Goldman DL; Casadevall A; Zuckier LS
J Med Vet Mycol; 1997; 35(4):271-8. PubMed ID: 9292424
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.
Casadevall A; Cleare W; Feldmesser M; Glatman-Freedman A; Goldman DL; Kozel TR; Lendvai N; Mukherjee J; Pirofski LA; Rivera J; Rosas AL; Scharff MD; Valadon P; Westin K; Zhong Z
Antimicrob Agents Chemother; 1998 Jun; 42(6):1437-46. PubMed ID: 9624491
[TBL] [Abstract][Full Text] [Related]
4. A Novel, Inexpensive In-House Immunochromatographic Strip Test for Cryptococcosis Based on the Cryptococcal Glucuronoxylomannan Specific Monoclonal Antibody 18B7.
Sathongdejwisit P; Pruksaphon K; Intaramat A; Aiumurai P; Sookrung N; Ratanabanangkoon K; Nosanchuk JD; Youngchim S
Diagnostics (Basel); 2021 Apr; 11(5):. PubMed ID: 33922698
[TBL] [Abstract][Full Text] [Related]
5. Structural and functional characterization of glycosylation in an immunoglobulin G1 to Cryptococcus neoformans glucuronoxylomannan.
Wang F; Nakouzi A; Alvarez M; Zaragoza O; Angeletti RH; Casadevall A
Mol Immunol; 2006 Mar; 43(7):987-98. PubMed ID: 16045988
[TBL] [Abstract][Full Text] [Related]
6. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.
Zebedee SL; Koduri RK; Mukherjee J; Mukherjee S; Lee S; Sauer DF; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Jul; 38(7):1507-14. PubMed ID: 7979280
[TBL] [Abstract][Full Text] [Related]
7. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen.
McLean GR; Torres M; Elguezabal N; Nakouzi A; Casadevall A
J Immunol; 2002 Aug; 169(3):1379-86. PubMed ID: 12133962
[TBL] [Abstract][Full Text] [Related]
8. Identification of Disease-Associated Cryptococcal Proteins Reactive With Serum IgG From Cryptococcal Meningitis Patients.
Gressler AE; Volke D; Firacative C; Schnabel CL; Müller U; Krizsan A; Schulze-Richter B; Brock M; Brombacher F; Escandón P; Hoffmann R; Alber G
Front Immunol; 2021; 12():709695. PubMed ID: 34367172
[No Abstract] [Full Text] [Related]
9. The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis.
Antinori S; Radice A; Galimberti L; Magni C; Fasan M; Parravicini C
J Clin Microbiol; 2005 Nov; 43(11):5828-9. PubMed ID: 16272534
[No Abstract] [Full Text] [Related]
10. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody.
Yuan R; Casadevall A; Spira G; Scharff MD
J Immunol; 1995 Feb; 154(4):1810-6. PubMed ID: 7836766
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab')2 and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection.
Dadachova E; Bryan RA; Huang X; Ortiz G; Moadel T; Casadevall A
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5629s-5635s. PubMed ID: 17875799
[TBL] [Abstract][Full Text] [Related]
12. Pre-antibiotic treatments spur modern fungal infection research.
Oncology (Williston Park); 1994 Nov; 8(11):16. PubMed ID: 7826836
[No Abstract] [Full Text] [Related]
13. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
14. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A
Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600
[TBL] [Abstract][Full Text] [Related]
15. Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding.
McClelland EE; Casadevall A
Fungal Genet Biol; 2012 Mar; 49(3):227-34. PubMed ID: 22327012
[TBL] [Abstract][Full Text] [Related]
16. Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis.
Brouwer AE; Teparrukkul P; Pinpraphaporn S; Larsen RA; Chierakul W; Peacock S; Day N; White NJ; Harrison TS
J Infect Dis; 2005 Aug; 192(4):681-4. PubMed ID: 16028138
[TBL] [Abstract][Full Text] [Related]
17. Cryptococcal Antigen Detection in Serum: Significance as a Screening Modality for Indian PLHIV.
Bajpai S
J Assoc Physicians India; 2017 Apr; 65(4):11-12. PubMed ID: 28527157
[No Abstract] [Full Text] [Related]
18. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
Beenhouwer DO; Shapiro S; Feldmesser M; Casadevall A; Scharff MD
Infect Immun; 2001 Oct; 69(10):6445-55. PubMed ID: 11553589
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
Govender NP; Roy M; Mendes JF; Zulu TG; Chiller TM; Karstaedt AS
HIV Med; 2015 Sep; 16(8):468-76. PubMed ID: 25689352
[TBL] [Abstract][Full Text] [Related]
20. Latex agglutination: diagnose the early cryptococcus neoformans test of capsular polysaccharide antigen.
Wang H; Yuan X; Zhang L
Pak J Pharm Sci; 2015 Jan; 28(1 Suppl):307-11. PubMed ID: 25631497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
